- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Taysha links gene therapy to motor gains in small Rett study | ||
| Di | Day One inks $1.2B biobucks pact for MabCare's solid tumor ADC | ||
| Di | Boston Scientific snags Silk Road Medical in $1.26B deal | ||
| Di | Zentalis' shares plunge 30% after FDA places WEE1 drug on partial hold over sepsis deaths | ||
| Di | Sanofi heads out to surf Belharra in $700M biobucks immunology deal | ||
| Di | Roche wades deeper into RNA waters, paying Ascidian $42M to develop exon editing drugs | ||
| Di | Malaria drug shows early potential as polycystic ovary syndrome treatment in rodents and people | ||
| Mo | J&J's DePuy Synthes orthopedics robot cleared for partial knee replacements | ||
| Mo | Siemens Healthineers nets European approval for blood test to predict MS relapse risks | ||
| Mo | Syncona merges Freeline and SwanBio to spur new gene therapy-focused biotech | ||
| Mo | FDA halts trial of BioNTech-MediLink ADC over 'significant risk of illness' | ||
| Mo | Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect | ||
| Mo | J&J's phase 2 Sjögren's data support FcRn strategy in the autoimmune disorder | ||
| Fr | New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded | ||
| Fr | FDA joins international push for transparency in AI development | ||
| Fr | Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more | ||
| Fr | J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund | ||
| Fr | Innovent braves bruising cytokine space, linking fusion protein to tumor responses in small study | ||
| Fr | enGene drops preclinical cystic fibrosis program to strengthen bladder cancer strategy | ||
| Fr | Radiopharma biotech Telix drops $200M Nasdaq IPO plans at last minute | ||
| Do | FDA elevates Medline recall of endotracheal ventilator tubes | ||
| Do | Invizius completes first-in-human dialysis trial to quell 'angry blood' | ||
| Do | AbbVie joins TL1A race via $150M upfront deal with China's FutureGen | ||
| Do | With MDMA debate spreading beyond biotech, Lykos CEO tries to dispel efficacy, safety concerns | ||
| Do | Ultragenyx wins surrogate endpoint debate, securing green light to seek FDA approval of gene therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
